Finally, tumors categorized as Triple-Negative BC (TNBC), which are negative for HER2, ER, and PgR, are usually associated with mutations in the breast cancer 1 (BRCA1) gene and represent the most aggressive and invasive BC type, with a mean of survival rate of 13 to 18 months after diagnosis [9]. This evidence concerns the gene ERBB2 and breast cancer.